Recent advances in the discovery of small molecule histone deacetylase inhibitors

Current Opinion in Drug Discovery and Development

Volumn 5, Issue 4, 2002, Pages 487-499

  Remiszewski, Stacy W ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

Apicidin; Cancer; CHAPs; FK 228; Histone deacetylase; MS 275; SAHA; Trapoxin; Trichostatin

Indexed keywords

2 AMINO 9,10 EPOXY 8 OXODECANOIC ACID; 3 [(3 CHOLAMIDOPROPYL)DIMETHYLAMMONIO] 1 PROPANESULFONIC ACID; AMINO ACID; APICIDIN; BUTYRIC ACID; CHLAMYDOCIN; CYCLO[LEUCYLPIPECOLYL (2 AMINO 8 OXO 9,10 EPOXYDECANOYL) DEXTRO PHENYLALANYL]; FR 901228; HC TOXIN; HISTONE; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; LYSINE; MS 27275; N (2 AMINOPHENYL) 2 PROPENAMIDE; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; OXAMFLATIN; PYROXAMIDE; PYRROL 2 YL 2 PROPENAMIDE INHIBITOR; PYRROLE DERIVATIVE; SODIUM PHENYLBUTYRATE; TETRAPEPTIDE; TRAPOXIN; TRAPOXIN A; TRICHOSTATIN A; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VORINOSTAT; ENZYME INHIBITOR; HISTONE DEACETYLASE;

ANTINEOPLASTIC ACTIVITY; CHROMATIN STRUCTURE; CRYSTAL STRUCTURE; CYTOTOXICITY; DRUG ACETYLATION; DRUG STRUCTURE; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMAN; NONHUMAN; REVIEW; STRUCTURE ANALYSIS; TUMOR CELL CULTURE; ANIMAL; DRUG ANTAGONISM; METABOLISM; METHODOLOGY; PHARMACEUTICS; SYNTHESIS;

ANIMALS; ENZYME INHIBITORS; HISTONE DEACETYLASES; HUMANS; TECHNOLOGY, PHARMACEUTICAL;

EID: 0036651788     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (84)

1. Woodcock CL, Dimitrov S: Higher-order structure of chromatin and chromosomes. Curr Opin Genet Dev (2001) 11:130-135. General introduction to nucleosome structure.
2. Komberg RD, Lorch Y: Twenty-five years of the nucleosome, fundamental particle of the eukaryote chromosome. Cell (1999) 98:285-294. Review of nucleosome structure and an introduction to chromatin remodeling.
3. Wu J, Grunstein M: 25 years after the nucleosome model: Chromatin modifications. Trends Biochem Sci (2000) 25:619-623.
4. Umov FD, Wolffe AP: Chromatin remodeling and transcriptional activation: The cast (in order of appearance). Oncogene (2001) 20:2991-3006.
5. Berger SL: An embarrassment of niches: The many covalent modifications of histones in transcriptional regulation. Oncogene (2001) 20:3007-3013.
6. Strahl BD, Allis CD: The language of covalent histone modifications. Nature (2000) 403:41-45. Proposal that histone modifications form a 'code' read by proteins to initiate downstream events.
7. Hansen JC, Tse C, Wolffe AP: Structure and function of the core histone N-termini: More than meets the eye. Biochemistry (1998) 37:17637-17641.
8. Gregory PD, Wagner K, Horz W: Histone acetylation and chromatin remodeling. Exp Cell Res (2001) 265:195-202.
9. Roth SY, Denu JM, Allis CD: Histone acetyltransferases. Annu Rev Biochem (2001) 70:81-120. Review of HATs.
10. Gray SG, Ekstrom TJ: The human histone deacetylase family. Exp Cell Res (2001) 262:75-83. Good review of the characteristics of HDACs known in 2001.
11. Khochbin S, Kao HY: Histone deacetylase complexes: Functional entities or molecular reservoirs. FEBS Lett (2001) 494:141-144.
12. Khochbin S, Verdel A, Lemercier C, Seigneurin-Bemy D: Functional significance of histone deacetylase diversity. Curr Opin Genet Dev (2001) 11:162-166. Good review of HDAC families and their diversity.
13. Caims BR: Emerging roles for chromatin remodeling in cancer biology. Trends Cell Biol (2001) 11:S15-S21.
14. Timmermann S, Lehrmann H, Polesskaya A, Harel-Bellan A: Histone acetylation and disease. Cell Mol Life Sci (2001) 58:728-736.
15. Mahlknecht U, Hoelzer D: Histone acetylation modifiers in the pathogenesis of malignant disease. Mol Med (2000) 6:623-644.
16. Cress WD, Seto E: Histone deacetylases, transcriptional control, and cancer. J Cell Physiol (2000) 184:1-16.
17. Cullis PM, Woffenden R, Cousens LS, Alberts BM: Inhibition of histone acetylation by N-[2-(S-coenzyme A)acetyl] spermidine amide, a multisubstrate analog. J Biol Chem (1982) 257:12165-12169.
18. Erwin BG, Persson L, Pegg AE: Differential inhibition of histone and polyamine acetylases by multisubstrate analogs. Biochemistry (1984) 23:4250-4255.
19. Parello J, Roblot G, Wylde R, Martin A: Chemical synthesis of multisubstrate inhibitors of histone acetyltransferase by covalently linking spermidine to an S-terminal fragment of coenzyme A. C R Acad Sci Ser 2 (1990) 310:1441-1446.
20. Wong LJ, Sharpe DJ: Regulation of nuclear histone acetyltransferase by nucleic acids, histone. DNA complex, and chromatin. Biochem Genet (1991) 29:13-28.
21. Roblot G, Wylde R, Martin A, Parello J: Regioselective synthesis of inhibitors of histone acetyl transferase covalently linking spermidine to the S-terminus of coenzyme A and fragments. Tetrahedron (1993) 49:6381-6398.
22. Broday L, Peng W, Kuo MH, Salnikow K, Zoroddu M, Costa M: Nickel compounds are novel inhibitors of histone H4 acetylation. Cancer Res (2000) 60:238-241.
23. Grozinger CM, Schreiber SL: Deacetylase enzymes. Biological functions and the use of small-molecule inhibitors. Chem Biol (2002) 9:3-16. Recent review of HDAC families, their protein complexes and mechanisms of deacetylation.
24. Patra SK, Patra A, Dahiya R: Histone deacetylase and DNA methyltransferase in human prostate cancer. Biochem Biophys Res Commun (2001) 287:705-713.
25. Choi JH, Kwon HJ, Yoon BI, Kim JH, Han SU, Joo HJ, Kim DY: Expression profile of histone deacetylase 1 in gastric cancer tissues. Jpn J Cancer Res (2001) 92:1300-1304.
26. Finnin MS, Donigian JR, Cohen A, Richon VM, Rifkind RA, Marks PA, Breslow R, Pavletich NP: Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature (1999) 401:188-193. First report on the structure of inhibitors bound to a deacetylase.
27. Riggs MG, Whittaker RG, Neumann JR, Ingram VM: n-Butyrate causes histone modification in HeLa and Friend erythroleukemia cells. Nature (1977) 268:462-464.
28. Boffa LC, Vidali G, Mann RS, Allfrey VG: Suppression of histone deacetylation in vivo and in vitro by sodium butyrate. J Biol Chem (1978) 253:3364-3366.
29. Lea MA, Tulsyan N: Discordant effects of butyrate analogues on erythroleukemia cell proliferation, differentiation and histone deacetylase. Anticancer Res (1995) 15:879-883.
30. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS: Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem (2001) 276:36734-36741.
31. Warrell RP Jr, He LZ, Richon V, Calleja E, Pandolfi PP: Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J Natl Cancer Inst (1998) 90:1621-1625.
32. Santini V, Gozzini A, Scappini B, Grossi A, Ferrini PR: Searching for the magic bullet against cancer: The butyrate saga. Leuk Lymphoma (2001) 42:275-289.
33. Gore SD, Carducci MA: Modifying histones to tame cancer: Clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors. Expert Opin Investig Drugs (2000) 9:2923-2934.
34. He LZ, Tolentino T, Grayson P, Zhong S, Warrell RP Jr, Rifkind RA, Marks PA, Richon VM, Pandolfi PP: Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J Clin Invest (2001) 108:1321-1330.
35. Nakajima H, Kim YB, Terano H, Yoshida M, Horinouchi S: FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp Cell Res (1998) 241:126-133.
36. Piekarz RL, Robey R, Sandor V, Bakke S, Wilson WH, Dahmoush L, Kingma DM, Tumer ML, Altemus R, Bates SE: Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: A case report. Blood (2001) 98:2865-2868. First report of the clinical responses from an HDAI administered as a single agent.
37. Saito A, Yamashita T, Mariko Y, Nosaka Y, Tsuchiya K, Ando T, Suzuki T, Tsuruo T, Nakanishi O: A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci USA (1999) 96:4592-4597. First report of preclinical efficacy with an orally administered HDAI.
38. Suzuki T, Ando T, Tsuchiya K, Fukazawa N, Saito A, Mariko Y, Yamashita T, Nakanishi O: Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives. J Med Chem (1999) 42:3001-3003.
39. Jung M, Brosch G, Koelle D, Scherf H, Gerhaeuser C, Loidl P: Amide analogues of trichostatin A as inhibitors of histone deacetylase and inducers of terminal cell differentiation. J Med Chem (1999) 42:4669-4679.
40. Yoshida M, Kijima M, Akita M, Beppu T: Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem (1990) 265:17174-17179.
41. waf1 promoter activity induced by histone deacetylase inhibitor in NIH3T3 cells. J Cell Biochem (1999) 73:291-302.
42. Hoshikawa Y, Kwon HJ, Yoshida M, Horinouchi S, Beppu T: Trichostatin A induces morphological changes and gelsolin expression by inhibiting histone deacetylase in human carcinoma cell lines. Exp Cell Res (1994) 214:189-197.
43. Lee E, Furukubo T, Miyabe T, Yamauchi A, Kariya K: Involvement of histone hyperacetylation in triggering DNA fragmentation of rat thymocytes undergoing apoptosis. FEBS Lett (1996) 395:183-187.
44. Vigushin DM, Ali S, Pace PE, Mirsaidi N, Ito K, Adcock I, Coombes RC: Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin Cancer Res (2001) 7:971-976.
45. Kim MS, Kwon HJ, Lee YM, Baek JH, Jang JE, Lee SW, Moon EJ, Kim HS, Lee SK, Chung HY, Kim CW, Kim KW: Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med (2001) 7:437-443.
46. Yoshida M, Hoshikawa Y, Koseki K, Mori K, Beppu T: Structural specificity for biological activity of trichostatin A, a specific inhibitor of mammalian cell cycle with potent differentiation-inducing activity in Friend leukemia cells. J Antibiot (1990) 43:1101-1106.
47. Li X, Yoshida M, Beppu T, Lotan R: Modulation of growth and differentiation of human colon carcinoma cells by histone deacetylase inhibitory trichostatins. Int J Oncol (1996) 8:431-437.
48. Sonoda H, Nishida K, Takayuki N, Yoshioka T, Ohtani M, Sugita K: Oxamflatin: A novel compound which reverses malignant phenotype to normal one via induction of JunD. Oncogene (1996) 13:143-149.
49. Ohtani M, Matsuura T, Shirahase K, Sugita K: (2E)-5-[3-[(phenylsulfonyl)amino]phenyl]-pent-2-en-4-ynohydroxamic acid and its derivatives as novel and potent inhibitors of ras transformation. J Med Chem (1996) 39:2871-2873.
50. Kim YB, Lee KH, Sugita K, Yoshida M, Horinouchi S: Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase. Oncogene (1999) 18:2461-2470.
51. Richon VM, Webb Y, Merger R, Sheppard T, Jursic B, Ngo L, Civoli F, Breslow R, Rifkind RA, Marks PA: Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc Natl Acad Sci USA (1996) 93:5705-5708.
52. Richon VM, Emiliani S, Verdin E, Webb Y, Breslow R, Rifkind RA, Marks PA: A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci USA (1998) 95:3003-3007.
53. Munster PN, Troso-Sandoval T, Rosen N, Rifkind R, Marks PA, Richon VM: The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res (2001) 61:8492-8497.
54. Huang L, Pardee AB: Suberoylanilide hydroxamic acid as a potential therapeutic agent for human breast cancer treatment. Mol Med (2000) 6:849-866.
55. Butler LM, Agus DB, Scher HI, Higgins B, Rose A, Cordon-Cardo C, Thaler HT, Rifkind RA, Marks PA, Richon VM: Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res (2000) 60:5165-5170.
56. Amin HM, Saeed S, Alkan S: Histone deacetylase inhibitors induce caspase-dependent apoptosis and downregulation of daxx in acute promyelocytic leukaemia with t(15;17). Br J Haematol (2001) 115:287-297.
57. Cohen LA, Amin S, Marks PA, Rifkind RA, Desai D, Richon VM: Chemoprevention of carcinogen-induced mammary tumorigenesis by the hybrid polar cytodifferentiation agent, suberanilohydroxamic acid (SAHA). Anticancer Res (1999) 19:4999-5005.
58. Butler LM, Webb Y, Agus DB, Higgins B, Tolentino TR, Kutko MC, LaQuaglia MP, Drobnjak M, Cordon-Cardo C, Scher HI, Breslow R, Richon VM, Rifkind RA, Marks PA: Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase. Clin Cancer Res (2001) 7:962-970.
59. Jung M, Hoffmann K, Brosch G, Loidl P: Analogs of trichostatin A and trapoxin B as histone deacetylase inhibitors. Bioorg Med Chem Lett (1997) 7:1655-1658.
60. Remiszewski SW, Sambucetti LC, Atadja P, Bair KW, Comell WD, Green MA, Howell KL, Jung M, Kwon P, Trogani N, Walker H: Inhibitors of human histone deacetylase: Synthesis and enzyme and cellular activity of straight chain details of hydroxamates. J Med Chem (2002) 45:753-757. Presents details of cell growth inhibition for an amide compound in human tumor cell lines.
61. Massa S, Mai A, Sbardella G, Esposito M, Ragno R, Loidl P, Brosch G: 3-(4-aroyl-1H-pyrrol-2-yl)-N-hydroxy-2-propenamides, a new class of synthetic histone deacetylase inhibitors. J Med Chem (2001) 44:2069-2072. Describes a novel heteroaromatic spacer.
62. Lavoie R, Bouchain G, Frechette S, Woo SH, Abou-Khalil E, Leit S, Foumel M, Yan PT, Trachy-Bourget MC, Beaulieu C, Li Z, Besterman J, Delorme D: Design and synthesis of a novel class of histone deacetylase inhibitors. Bioorg Med Chem Lett (2001) 11:2847-2850.
63. Stemson SM, Wong JC, Grozinger CM, Schreiber SL: Synthesis of 7200 small molecules based on a substructural analysis of the histone deacetylase inhibitors trichostatin and trapoxin. Org Lett (2001) 3:4239-4242.
64. Meinke PT, Liberator P: Histone deacetylase: A target for antiproliferative and antiprotozoal agents. Curr Med Chem (2001) 8:211-235.
65. Staehelin H, Trippmacher A: Cytostatic activity of chlamydocin, a rapidly inactivated cyclic tetrapeptide. Eur J Cancer (1974) 10:801-808.
66. Shute RE, Dunlap B, Rich DH: Analogs of the cytostatic and antimitogenic agents chlamydocin and HC-toxin: Synthesis and biological activity of chloromethyl ketone and diazomethyl ketone-functionalized cyclic tetrapeptides. J Med Chem (1987) 30:71-78.
67. Darkin-Rattray SJ, Gumett AM, Myers RW, Dulski PM, Crumley TM, Allocco JJ, Cannova C, Meinke PT, Colletti SL, Bednarek MA, Singh SB, Goetz MA, Dombrowski AW, Polishook JD, Schmatz DM: Apicidin: A novel antiprotozoal agent that inhibits parasite histone deacetylase. Proc Natl Acad Sci USA (1996) 93:13143-13147.
68. WAF1/CIP1 by apicidin, a novel histone deacetylase inhibitor. Biochem Biophys Res Commun (2001) 281:866-871.
69. WAF1/Cip1 and gelsolin. Cancer Res (2000) 60:6068-6074.
70. Kwon SH, Ahn SH, Kim YK, Bae GU, Yoon JW, Hong S, Lee HY, Lee YW, Lee HW, Han JW: Apicidin, a histone deacetylase inhibitor, induces apoptosis and Fas/Fas ligand expression in human acute promyelocytic leukemia cells. J Biol Chem (2002) 277:2073-2080.
71. Meinke PT, Colletti SL, Doss G, Myers RW, Gumett AM, Dulski PM, Darkin-Rattray SJ, Allocco JJ, Galuska S, Schmatz DM, Wyvratt MJ, Fisher MH: Synthesis of apicidin-derived quinolone derivatives: Parasite-selective histone deacetylase inhibitors and antiproliferative agents. J Med Chem (2000) 43:4919-4922.
72. Colletti SL, Myers RW, Darkin-Rattray SJ, Gumett AM, Dulski PM, Galuska S, Allocco JJ, Ayer MB, Li C, Lim J, Crumley TM, Cannova C, Schmatz DM, Wyvratt MJ, Fisher MH, Meinke PT: Broad spectrum antiprotozoal agents that inhibit histone deacetylase: Structure-activity relationships of apicidin. Part 1. Bioorg Med Chem Lett (2001) 11:107-111.
73. Colletti SL, Myers RW, Darkin-Rattray SJ, Gumett AM, Dulski PM, Galuska S, Allocco JJ, Ayer MB, Li C, Lim J, Crumley TM, Cannova C, Schmatz DM, Wyvratt MJ, Fisher MH, Meinke PT: Broad spectrum antiprotozoal agents that inhibit histone deacetylase: Structure-activity relationships of apicidin. Part 2. Bioorg Med Chem Lett (2001) 11:113-117.
74. Furumai R, Komatsu Y, Nishino N, Khochbin S, Yoshida M, Horinouchi S: Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. Proc Natl Acad Sci USA (2001) 98:87-92. List of cyclic peptide hydroxamates and their activities in human HDAC-1 and mouse HDAC-6.
75. Komatsu Y, Tomizaki KY, Tsukamoto M, Kato T, Nishino N, Sato S, Yamori T, Tsuruo T, Furumai R, Yoshida M, Horinouchi S, Hayashi H: Cyclic hydroxamic-acid-containing peptide 31, a potent synthetic histone deacetylase inhibitor with antitumor activity. Cancer Res (2001) 61:4459-4466.
76. Taunton J, Hassig CA, Schreiber SL: A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. Science (1996) 272:408-411.
77. Taunton J, Collins JL, Schreiber SL: Synthesis of natural and modified trapoxins, useful reagents for exploring histone deacetylase function. J Am Chem Soc (1996) 118:10412-10422.
78. CHEMOTHERAPEUTISCHES FORSCHUNGSINSTITUT GEORG-SPEYER-HAUS (Göttlicher M, Heinzel T, Groner B, Herrlich P): Valproic acid and derivatives thereof as histone deacetylase inhibitors. EP-01170008 (2002).
79. FUJISAWA PHARMACEUTICAL CO LTD (Okuhara M, Goto T, Hori Y, Fujita T, Ueda H, Shigematsu N): FR901228 substance and preparation thereof. EP-00352646 (1990).
80. METHYLGENE INC (Delorme D, Ruel R, Lavoie R, Thibault C, Abou-Khalil E): Inhibitors of histone deacetylase. WO-00138322 (2001). Lists a variety of HDA/structural types.
81. METHYLGENE INC (Delorme D, Woo SH, Vaisburg A): Inhibitors of histone deacetylase. WO-00170675 (2001) List a variety of HDA/structural types.
82. SHIONOGI AND CO LTD (Ohtani M, Arita H, Sugita K, Matsuura T, Shirahase K): Preparation of sulfonamidoaryl hydroxamic acids as inflammation and tumor inhibitors. WO-09312075 (1993).
83. SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH/COLUMBIA UNIVERSITY (Breslow R, Marks PA, Rifkind RA, Jursic B): Novel potent inducers of terminal differentiation and methods of use thereof. WO-09307148 (1993).
84. PRESIDENT AND FELLOWS OF HARVARD COLLEGE (Schreiber SL, Taunton J, Hassig CA, Jamison TF): Histone deacetylases, and uses related thereto. WO-09735990 (1997).